BGB324: Phase I data

Data from 24 patients with previously treated AML or high-risk myelodysplastic syndrome (MDS) in Part A of

Read the full 173 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE